Supplementary tables

Table S1. Clinical responses and survival of patients with durable clinical benefit

Patient	Clinical Response	Survival (months)	Alive
P5	Partial response	55	Yes
P6	Partial response	52	Yes
P12	Complete response	48	Yes
P13	Partial response	47	Yes
P27	Partial response	21	No
P26	Stable disease	36	Yes
PBI-12	Stable disease	31	Yes

Table S2. Time between pre-treatment and post-treatment samples and the fold changes for Gal-1 antibodies

	N	Mean	S.D.	Min	Median	Max
Weeks between samples	43	10.2	3.4	4.7	9.0	18.0
Gal-1 antibody fold changes	43	1.5	1.0	0.3	1.1	4.2

Table S3. Distribution of patients with humoral immune responses to Gal-1

	CR	PR	SD	PD	CR/PR
Patient #	1	7	22	13	8
Patient # with Gal-1 Ig increase	1	4	8	3	5
% Patients with Gal-1 Ig increase	100	57.1	36.4	23.1	62.5

CR, complete response; PR, partial response; SD, stable disease; and PD, progressive disease.

Table S4. The relationship between response and Gal-1 antibody change

Gal-1 Ig fold change ≥ 1.5?	Complete response/partial response?				Fisher's Exact p-value
	No N=20		Yes N=7		
	N	%	N	%	
No	13	86.7	2	13.3	0.19
Yes	7	58.3	5	41.7	

Table S5. H-scores of Gal-1 staining in pre-treatment and post-treatment tumor biopsies

Clinical response	Patient	Tumor cells		Endothelial cells	
		Pre	Post	Pre	Post
PR	P27	20	300	0	270
	P20	240	270	0	300
	P1	0	0	180	180
SD	P9	180	200	90	240
	P31	300	300	n/a	n/a
	PMGH1	180	0	80	0
PD	P4	160	270	210	240
	P28	270	120	60	0

H-scores were calculated by multiplying the percentage of positive cells with their intensity (1, 2 or 3). PR, partial response; SD, stable disease; and PD, progressive disease.